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Abstract 
Background: Langerhans cell histiocytosis (LCH) is a rare disease that originates from the uncontrolled proliferation 
and accumulation of bone marrow-derived immature myeloid dendritic cells. Dendritic cells are a type of histiocyte 
that play an important role in the human immune system and are found in the bone, skin, stomach, eyes, intestines, 
and lungs.
Objective: This systematic review aimed to collect and report published case reports of rare bone disease caused by 
LCH to avoid misdiagnoses or delays in diagnosis.
Methods: We systematically searched Scopus, PubMed, Embase, and Web of Sciences from August 1, 2000 to 
December 31, 2019. Studies reporting cases of LCH with rare bone involvement were included.
Results: We identified 60 articles including 64 cases. Of the identified cases, 31 (48.4%) involved children, and 33 
(51.6%) involved adults. Additionally, 46.9% (30 individuals) were from Asian countries. The mean age of the children 
was 7.6 ± 4.3 years and that of the adults was 36 ± 12 years. The findings indicated that unifocal bone involvements 
were the most prevalent form of the disease (68.7%), and, overall, the skull and chest wall were the most commonly 
affected bones in both adults and children. The spine and long bones were the second most commonly affected 
bones in children, and the spine and jaw were the second most commonly affected bones in adults. Pain and swelling 
were the most frequent presenting signs among the investigated cases, and loss of consciousness, myelopathy, nerve 
palsy, visual loss, torticollis and clicking sounds were rare signs. Osteolytic lesions were the most frequent radiologic 
feature (62.5%), and intracranial hemorrhage, fluid–fluid level, dura and intracranial extension and pathologic frac-
tures were rare radiological features. Total excision, curettage and observation in the unifocal group of patients and 
systemic chemotherapy in the other groups (i.e., multifocal and multisystem) were the most frequent management 
approaches. The recovery rates of the unifocal and multifocal groups were 77.3% and 81.8%, respectively, while that of 
the multisystem group was 55.5%. The rates of recurrence and mortality in the multisystem group were 11% and were 
higher than those in the other groups.
Conclusions: LCH is a rare disease that can affect any organ in the human body. However, bone is the most com-
monly involved organ, and rare bone involvements may be the first or only symptom of the disease due to the rarity 
of such lesions; a lack of familiarity with them may result in misdiagnosis or delayed diagnosis.
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Introduction
Langerhans cell histiocytosis (LCH) is a rare disease with 
a prevalence of 2–5 cases per million in children and 
1–2 cases per million in adults annually [1, 2]. The etiol-
ogy and pathogenesis of the disease remain unclarified; 
earlier theories stated that LCH is a reactive process, but 
recent findings based on the identification of oncogenic 
BRAF or MAP2K1 mutations in most cases of LCH sug-
gest that it is a clonal neoplasm and originates from the 
uncontrolled proliferation and accumulation of bone 
marrow-derived immature myeloid dendritic cells [3–6]. 
LCH predominantly affects children ages 5 to 15  years, 
with a mean age of 3 years [2, 3] and is more prevalent 
in male cases than in female cases [2, 6]. Its presentation 
in neonates and adults is rare [7] and in those older than 
50 years is an exception [8].
Abnormal dendritic cells can infiltrate any organ, and, 
depending on the number and site of involved organs, 
the disease was previously classified as unifocal LCH 
with a solitary bone lesion (eosinophilic granuloma), 
multisystem with bone involvement, diabetes insipidus, 
exophthalmos (Hand–Schüller–Christian disease) and 
disseminated involvement with risk organ dysfunction 
(Abt–Letterer–Siwe syndrome) [9]. Recently, based on 
the revised classification of histiocytoses, LCh has been 
subclassified as follows: single-system LCH, lung LCH 
and multisystem LCH with or without risk organ involve-
ment (liver, spleen, and bone marrow) [10]. The most 
common form of the disease is single-system LCH of the 
bone (approximately 75–80%) [3, 10], which can manifest 
as a uni- or multifocal form [2, 6]. The unifocal form is 
more common than the multifocal form.
LCH can affect any bone, but more than 50% of bone 
lesions belong to the skull, ribs and pelvis. The auditory 
ossicles, inner ear, sphenoid wings, clivus, and the short 
tubular bones of the hands and feet are rarely involved 
[9]. Pain, swelling, soft tissue mass, and, occasionally, 
bone deformity and bone fracture are symptoms of iso-
lated bone involvement, but systemic symptoms are less 
common [11].
The diagnosis of bone lesions is based on imaging stud-
ies and histopathological examination. Radiography is the 
gold standard of imaging studies, and computed tomog-
raphy (CT), magnetic resonance imaging (MRI), bone 
scintigraphy, positron emission tomography–computed 
tomography (PET–CT) and whole-body MRI are comple-
mentary imaging studies. The most common radiologic 
feature of the bone involvements is a lytic lesion that 
may present as a moth-eaten, punched-out, geographic 
or expansile form [9]. Destructive bone lesions or erosive 
forms are less common. Histopathological examination 
and immunohistochemical staining (with CD1a, S100 
protein, and/or CD207 antibodies) of tissue samples are 
necessary to confirm bone lesions [5, 9].
The treatment and outcome of bone lesions depend 
on the extent and severity of the disease. Unifocal bone 
involvements are the least severe form of the disease and 
are usually treated locally by excision, curettage, intral-
esional steroid injection or radiation therapy [6, 9]. The 
outcome of such treatment has been good, and more 
than 80% of the patients recover completely [5, 6, 11]. 
However, multifocal bone involvements and multisys-
tem disease with bone involvements require systemic or 
combination therapies and their prognosis depends on 
the site of bone involvement and accompanying involved 
organs. Multisystem involvement with “risk organs” has 
the worst prognosis [5, 9].
Because of the relative rarity of LCH, we conducted this 
systematic review to collect and identify clinical presen-
tations, methods of diagnosis, treatment and outcomes of 
rare cases of LCH with bone involvement to avoid misdi-
agnoses or delays in diagnosis.
Method
Search strategies and information sources
In this study, the rare osseous involvement of LCH in 
children and adults was reviewed. A literature search 
was conducted in Scopus, PubMed, Embase, and Web 
of Sciences from August 01, 2000 to December 31, 2019. 
Appropriate English keywords such as “Langerhans cell 
histiocytosis”, “Hand-Schueller-Christian syndrome”, 
“bone”, “skull”, “case report”, and other similar keywords 
were used to search the articles in the databases. To iden-
tify any remaining studies, we hand-searched the bib-
liographies of all the included studies, relevant review 
articles, and the internet. The full search strategy is avail-
able in the “Appendix”.
Eligibility criteria
All the case reports on rare cases of LCH disease that 
described and reported bone involvement and were 
published in the English language were included in our 
search regardless of patient age. Case reports that did not 
document (I) demographic characteristics, (II) site(s) of 
involvement, (III) symptoms and signs, and (IV) method 
of diagnosis were omitted from the list of the articles. 
Reviews and meta-analyses, proceeding articles, editori-
als and letters, news articles, posters, conference articles, 
Keywords: Langerhans cell histiocytosis, LCH disease, Bone lesion, Rare disease, Children, Adults, Systematic review
Page 3 of 13Reisi et al. Orphanet J Rare Dis            (2021) 16:1  
book chapters, poorly described cases or case series with-
out primary data or without a description of individual 
patient data and articles without author names were also 
excluded.
Study selection
In the first step, the stated data sources were searched 
by the third author (Touraj Harati Khalilabad) and the 
extracted articles were imported into the reference 
management software ENDNOTE. After removing 
duplicates, the remaining articles were screened by first 
author (Nahid Reisi) using the title and abstract infor-
mation. In the second step, the full text of the articles 
was checked by two trained authors (Alireza Moafi and 
Pouran Raeissi) to assess their inclusion. Each article was 
reviewed by two individuals independently, and if the 
authors had opposing opinions about an article, the first 
reviewer (Nahid Reisi) evaluated the article.
A “rare case” of LCH in this review was defined as 
follows:
I, Bone involvement in unusual locations such as the 
auditory ossicles and internal ear, clivus, sphenoid bone 
with involvement of the clivus, sphenoid wings or pitui-
tary stalk [9], clavicle, sternum, forearm, fibula, short 
tubular bones of hand and foot, and lesions crossing a 
cranial suture [9, 12–15].
II, Atypical radiographic appearance such as epiphy-
seal lesions, transphyseal lesions, extracranial “button 
sequestrum”, posterior vertebral arch lesions of the spine, 
fluid–fluid levels on CT or MRI, cortical bone lesions, 
extension of a lesion into the dura or brain substance, 
and pathologic fractures [12, 13], and/or extradural 
hematoma of skull LCH [9].
III, Unusual presentations such as neurologic manifes-
tations of spinal disease resulting from vertebral collapse 
and impingement or from extradural extension of the 
lesion [12] and cranial nerves palsy [9].
IV, Unusual age—the neonatal period [7] and age older 
than 50 years [8].
Data extraction
In the final step, the required parameters and character-
istics of each study were extracted and included author 
names, year, country of origin of the published article, 
demographic characteristics of the cases, symptoms and 
signs, sites of involvement, lesion types, method of tissue 
sampling and diagnosis, strategies for management and 
patient outcomes.
Results
The results of the initial search of databases and hand 
searching other sources yielded 2,101 and 22 arti-
cles, respectively; after eliminating duplicates, 1,661 
articles remained. After screening the articles by title and 
abstract, 264 articles remained, and the remainder were 
excluded because they were not relevant. After review-
ing the full text of the 264 articles, 113 articles that lacked 
eligibility information were excluded. Finally, 60  articles 
encompassing  64  rare cases met the eligibility criteria 
to enter the study [2–4, 6–8, 14–67]. Figure 1 shows the 
flow diagram of the literature search.
Demographic characteristics
Sixty articles were included in the final analysis, com-
prising 64 cases. Most of the case reports (71.7%) were 
published between 2010 and 2019 and were from 
Asian countries. More than two-thirds (70.3%) of the 
cases were male, and the male-to-female ratio was 2.3. 
Thirty-one cases (48.4%) were children (younger than 
18  years), and the remainder (51.6%) comprised adults 
(older than 18 years). The mean age of the children was 
7.3 years (SD = 4.3 years) with an age range of 5 months 
to 16 years, and the mean age of the adults was 36 years 
(SD = 12 years) with an age range of 18–66 years
Based on the number of involved bones and other 
organ involvement, the cases were classified into three 
categories: unifocal bone involvement, multifocal bone 
involvement, and multisystem. Unifocal bone involve-
ment had the highest frequency among the other groups 
of bone involvement and accounted for 68.7% of the 
cases.
In general, the skull and chest wall showed the highest 
rate of involvement (42.2% and 23.4%, respectively) fol-
lowed by the spine and pelvis (9.4% each). Short tubular 
bones were involved in 3% of the cases. The demographic 
and clinical characteristics of the included cases are 
shown in Table 1.
Symptoms and signs
Table 2 depicts the symptoms and signs of the included 
cases. Localized pain (48.4%) and swelling (26.5%) were 
the most frequent presenting symptoms and signs, fol-
lowed by headache (15.6%), hearing loss (12.5%), local-
ized mass (9.4%) and limitation of motion (9.4%).
Hearing loss, otalgia, otorrhea, tinnitus, vertigo, nys-
tagmus and disequilibrium were symptoms and signs of 
temporal bone involvement with extension and destruc-
tion of the inner ear. Left otitis media with effusion 
and drainage of cerebrospinal fluid (CSF) after ventila-
tion tube insertion was a rare presentation of mastoid 
involvement with destruction of the posterior wall of 
the external auditory canal with extension to the sig-
moid sinus. Hearing loss in both ears for 10 years treated 
with corticosteroids and worsening following the discon-
tinuation of corticosteroids was another sign of mastoid 
involvement.
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Headache, vomiting, loss of consciousness, swell-
ing and soft tissue mass (progressive or tender with 
or without pain) were symptoms and signs of calva-
rium bone involvements with intracranial hemorrhage. 
Facial puffiness and eye proptosis was a sign of maxil-
lary sinus involvement. Rapidly progressing visual loss 
occurred following optic canal involvement (1 case) 
and gradual visual loss following petrous apex involve-
ment (2 cases). Bilateral abducent nerve palsy was also 
another sign of petrous apex involvement.
Symptoms of cord compression, including pain, 
weakness, numbness, paresis and paresthesia, were 
observed in 3 cases with spinal involvements and 1 case 
of sacral spine (S1) involvement with extension into the 
neuroforamina. Torticollis was also reported in cases 
with cervical spine or occipital condyle involvement.
The other rare symptoms in these cases were chest 
tightness, clicking sound (due to pathological frac-
ture of the clavicle), teeth mobility and gingival dehis-
cence. Fever was also reported in one case with sternum 
involvement.
Sites of bone involvement
The findings indicated that most of the cases showed 
unifocal bone involvement (68.75%). Multifocal and mul-
tisystem bone involvements were observed in (17.19%) 
and (14.06%) of the cases, respectively. The sites of bone 
involvement in children and adults for the three stated 
categories are presented in Table 3 and Figs. 2, 3, 4.
Of the 64 identified cases, 31 were children and 33 
were adults; the prevalence of the disease did not dif-
fer between the two groups based on our findings. For 
the two groups, the most common affected bones were 
Fig. 1 PRISMA flow diagram of literature search
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as follows: in children: skull (48.4%), chest wall (22.6%), 
spine and long bones (each 9.7%); in adults: skull 
(36.4%), chest wall (21.2%), spine (9.1%) and jaw (6.1%). 
TPelvic bone involvement was observed exclusively in 
adults, and involvement of the short tubular bones of 
the hand and foot did not differ between the two age 
groups (Table 3 and Fig. 5).
In the skull, calvarium involvements were more 
prevalent than in the skull base, and mostly involved 
children. However, the parietal and occipital regions 
were the most affected sites, and intracranial hemor-
rhage was exclusively observed in children. Skull base 
involvements, which mostly affected the inner ear, were 
more prevalent in adults (Table 3).
Imaging studies, type of bone lesions and tissue sampling 
methods
Table  4 summarizes the imaging studies, types of bone 
lesions and tissue sampling methods of all the cases.
The most common types of imaging studies used in all 
the patient groups were CT (47 cases; 73.4%) and MRI 
(46 cases; 71.9%), followed by plain radiography (46.9%), 
bone scintigraphy (34.4%), bone survey (21.9%) and PET-
CT (15.6%).
Radiologically, osteolytic lesions, with a prevalence of 
62.5% (n = 40), were the most common bone involvement 
among the cases, followed by destructive, expansile lytic 
and erosive forms, in that order. In a 66-year-old man 
with a parietal osteolytic lesion, a sequestered fragment 
within the lesion (button sequestrum) was reported. 
Another study reported a 4  year old with LCH discrete 
fluid–fluid levels within the epidural component.
The findings indicated that, in 98.4% (n = 63) of 
cases, the diagnoses of bone LCH was confirmed by 
Table 1 The demographic and  clinical characteristics 
of rare cases of bone involvement (n = 64)
a Mandible, maxilla, nasal bones and orbit
b Rib, clavicle, sternum and scapula




 Asia 30 (46.9)
 Europe 19 (29.7)
 America 12 (18.7)
 Africa 2 (3.1)
 Oceania 1 (1.6)
Gender
 Male 45 (70.3)
 Female 19 (29.7)
Age (years)
 Less than 1 2 (3.2)
 2–18 29 (45.2)
 19–50 28 (43.8)
 More than 50 5 (7.8)
Category
 Unifocal 44 (68.7)
 Multifocal 11 (17.2)
 Multisystem 9 (14.1)
Site of bone involvement
 Skull 27 (42.2)
 Facial  bonesa 4 (6.2)
 Spine 6 (9.4)
 Chest  wallb 15 (23.4)
 Pelvis 6 (9.4)
 Long bones 4 (6.2)
 Short tubular bones 2 (3.1)
Mean age (years) Mean ± SD (n)
 Children (Age range in children) 7.6 ± 4.3 (n = 31)
 Adults (Age range in adults) 36.4 ± 12 (n = 33)
Table 2 Symptoms and  signs of  rare bone involvements 
of LCH cases (n = 64)
n (%)
Symptom and sign
 Localized pain 31 (48.4)
 Swelling ± pain 17 (26.5)
 Headache ± vomiting 10 (15.6)
 Hearing loss 8 (12.5)
 Mass ± tenderness 6 (9.4)
 Limitation of motion 6 (9.4)
 Loss of consciousness 4 (6.2)
 Vertigo 4 (6.2)
 Visual loss 3 (4.7)
 Torticollis 3 (4.7)
 Tinnitus 2 (3.1)
 Otalgia 2 (3.1)
 Otorrehea 2 (3.1)
 Numbness 2 (3.1)
 Weakness 2 (3.1)
 Nerve palsy 1 (1.5)
 Quadruparesis 1 (1.5)
 Paresthesia 1 (1.5)
 Hyposthesia 1 (1.5)
 Disequilibrium 1 (1.5)
 Nystagmus 1 (1.5)
 Proptosis 1 (1.5)
 Chest tightness 1 (1.5)
 Clicking sound 1 (1.5)
 Teeth mobility 1 (1.5)
 Gingival dehiscent 1 (1.5)
 Afternoon fever 1 (1.5)
Page 6 of 13Reisi et al. Orphanet J Rare Dis            (2021) 16:1 
histopathological and immunohistochemical examina-
tion on tissue sampling of the lesion. In one case, tissue 
sampling of the lesion was not performed, and the diag-
nosis was merely made based on the clinical background 
of LCH and imaging examinations. Surgical biopsy 
(43.7%) and closed biopsy (18.7%) were the most frequent 
methods of sampling.
Management approach and outcomes
Table  5 summarizes the treatment modalities used 
to treat the LCH bone lesion patients, along with the 
outcomes.
In the unifocal group, total excision (40.9%), curet-
tage (20.5%) and observation (9%) were the most fre-
quent modalities applied to treat the patients, followed 
by “excision plus chemotherapy”, “curettage plus radio-
therapy”, “systemic chemotherapy”, and “conservative 
management” (4.5% each). However, “subtotal excision 
plus radiotherapy” or “sub-total excision plus chemother-
apy”, “radiotherapy plus epidural steroid injection”, radio-
therapy and radiosurgery alone were the least common 
modalities applied to treat LCH patients (2.5% each).
Among the multifocal and multisystem categories, 
“systemic chemotherapy” was the most frequent manage-
ment approach applied (36.3% and 33.3%, respectively), 
followed by total excision in the multifocal cases and 
combination therapies (total excision + chemotherapy, 
subtotal excision + chemotherapy, chemotherapy + radi-
otherapy, and analgesics + intraregional steroid) in the 
multisystem group (18.2% and 44.4%, respectively). Two 
Table 3 Sites of bone involvement in children and adult LCH cases (n = 64)
Site of bone involvement Child Adult
Unifocal Multifocal Multisystem Unifocal Multifocal Multi system
Calvarium 10 0 1 1 1 2
Skull base 2 2 0 5 2 1
Facial bones 0 0 1 0 3 0
Spine 2 1 0 3 0 0
Chest wall 7 1 0 7 0 0
Pelvis 0 0 0 4 0 2
Long bone 1 1 1 0 0 1
Short tubular bones 1 0 0 1 0 0
23 5 3 21 6 6
Fig. 2 Sites of bone involvement in adults and children in unifocal sub-group
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patients in the unifocal group and 1 patient in the multi-
system and multifocal groups were treated by conserva-
tive management.
Following the initial treatments, 77.3% of the unifo-
cal, 81.8% of the multifocal and 55.5% of the multisystem 
cases completely recovered, but permanent complica-
tions were reported in six patients (9.4%) (1 in the unifo-
cal, 3 in the multifocal, and 2 in the multisystem group). 
The multisystem group had more recurrences than 
the unifocal and multifocal groups (11% vs 2% and 9%, 
respectively), and the mortality rate in this group was 
higher than that in the other two groups (11% vs 0.0%).
Discussion
The results of this systematic review of rare case reports 
of LCH bone involvements showed differences and simi-
larities with the existing literature. The cause may be 
that the available statistics are mostly based on studies 
Fig. 3 Sites of bone involvement in adults and children in multifocal sub-group
Fig. 4 Sites of bone involvement in adults and children in multisystem sub-group
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concerning LCH in general and not rare cases. Further-
more, most of the findings of rare cases were obtained 
from a few cases, not systematic reviews, highlighting the 
need for these studies.
Our findings showed that most cases (70%) of rare 
LCH bone involvements occurred in male patients and 
the M/F ratio was 2.3. This finding was consistent with 
previous study findings [3, 6, 11]. However, unlike studies 
reporting that LCH disease is more prevalent in children, 
and rare in adults [2, 4, 6, 68], our findings showed no 
difference between the two groups [children = 31 cases 
(48.44%); adults = 33 cases (51.56%)].
Additionally, the mean age of the children in this study 
was 7.6 years, higher than that of children with the dis-
ease in other studies (3  years) [3]. The explanation for 
such differences is not clear but may indicate that most 
bone involvements of LCH occur at an older age or may 
be due to our inclusion of rare cases [4].
Our findings also revealed that the unifocal form 
(68.7%) was the most common form of bone involvement 
and the unifocal/multifocal ratio was 4:1. Singh et al. [63] 
also reported an average ratio of 3:1 (range 2:1 to 6:1) for 
monostotic-polyostotic lesions, and Tsuchie et  al. [61] 
reported a high prevalence (79%) of solitary bone lesions.
Based on the available statistics, the skull is the most 
common site of bone involvement of LCH (40–60% of 
cases) [1, 11, 14, 61, 62, 67, 69], followed by the femur, rib, 
vertebra, and humerus in children [69] and isolated flat 
bone involvement in adults [1]. In only one study, the pri-
mary sites of bone involvement in adults were reported 
Fig. 5 Sites of bone Involvement in adults and children
Table 4 Imaging studies, type of  lesions and  tissue 
sampling methods of  LCH bone lesions in  cases (n = 64) 
of case reports




 Plain radiograph 30 (46.9)
 CT scan 47 (73.4)
 MRI 46 (71.9)
 Bone survey 14 (21.9)
 Bone scintigraphy 22 (34.4)
 PET/CT 10 (15.6)
Type of lesions
 Osteolytica 40 (62.5)
 Destructive 11 (17.2)
 Expansile lytic 8 (12.5)
 Erosive 5 (7.8)
Tissue sampling method
 Surgical biopsy 28 (43.7)
 Closed biopsy 12 (18.7)
 Open biopsy 11 (17.2)
 Needle biopsy 6 (9.4)
 CT-guided biopsy 5 (7.8)
 Curettage biopsy 1 (1.6)
 Sampling was not removed 1 (1.6)
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as follows: jaw (30%), skull (21%), extremity (17%), verte-
bra and pelvis (13% each), and rib (6%) [69].
The prevalence of bone involvements in children and 
adults showed the following differences: long bones 
(17%) with a higher tendency in children [1], jaw (8% in 
children, 30% in adults) [11, 69], pelvis (8%–13%) with a 
higher tendency in adults [1, 4, 69], ribs (8% in children, 
Table 5 Management and outcome of bone lesions in cases (n = 64) of case reports
SCC, semicircular canal; C2, second cervical spine; T6, sixth thoracic spine
a  3 cases, b 2 cases
Management n (%) / involved sites References
Unifocal (n = 44) Multifocal (n = 11) Multisystem (n = 9)
Total excision 18 (40.9)/skull, spine, 
sternum
2 (18.2)/temporal + intracra-
nial extention + sigmoid 
sinus, + mandible, Both 
jaws
– [8, 16, 18, 20, 22–31, 40, 42, 
52, 57]a
Total excision + chemo-
therapy
2 (4.5)/spine, rib 1 (11.1)/
petrous + SCC + middle 
cranial base
[34, 38, 64]
Subtotal excision + chemo-
therapy





Subtotal excision + radio-
therapy
1 (2.3)/spine 1 (9.1)/clivus, sella + sphe-
noid sinus
[33, 60]
Radiosurgery 1 (2.3)/skull – – [17]
Radiotherapy 1 (2.3)/spine 1 (9.1)/temporal + cli-
vus + occipital + atlanto-
axial joint
– [32, 54]
Radiotherapy + epidural 
steroid injection
1 (2.3)/ [51] – – [51]
Systemic chemotherapy 2 (4.5)/clavicle, skull 4 (36.3) /odontoid pro-
cess + C2 + femur, bilateral 
petrous + bilateral laby-
rinth, both jaws + petrous 
apex + otic capsule + cli-
vus, sternum + greater 
trochanter + tibia
3 (33.3)/bilateral pari-
etal + both jaws, maxillary 
sinus, Ilium + T6 + 6th rib




– – 1 (11.1)/temporal with 
involving dura
[3]
Analgesics, + intralesional 
steroid injection + chemo-
therapy
– – 1 (11.1)/both femur [66]
Curettage 9 (20.5)/clavicle, sternum, 
humerus, acetabulum, 
metatarsal
– – [14, 36–38, 41, 43, 49, 50]b
Curettage + radiotherapy 2 (4.5)/sternum, metacarpal – – [15, 45]
Observation 4 (9.0)/sternum, clavicle, 
scapula, ilium
– – [4, 39, 44]
Conservative 2 (4.5)/scapula, spine 1 (9.1)/radius, ulna 1 (11.1)/femur [2, 35, 46, 63]
Not determined – 1 (9.1)/both jaws 1 (11.1)/sacral [56, 67]
Outcome after initial treat-
ment
n (%)
Complete recovery without 
complication
33 (75.0) 6 (54.5) 3 (33.3)
Complete recovery with 
permanent complication
1 (2.3) 3 (27.3) 2 (22.2)
Recurrence 1 (2.3) 1 (9.1) 1 (11.1)
Lost follow- up 1 (2.3) 0 (0.0) 0 (0.0)
Not determined 8 (18.1) 1 (9.1) 2 (22.2)
Death 0 (0.0) 0 (0.0) 1 (11.1)
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6%–25% in adults) [1, 69], and spine (3%–30%) with a 
slightly higher tendency in children [57].
In the present study, the prevalence of bone involve-
ment of LCH disease was as follows:
In children: skull (48.4%), chest wall (22.6%), spine and 
long bones (9.7% each); in adults: skull (36.4%), chest wall 
(21.2%), spine (9.1%) and jaw (6.1%). Consistent with pre-
vious studies [1, 9, 14, 61, 67, 69], our findings revealed 
that the skull was the most commonly involved site, and 
calvarium involvements were more common than the 
skull base.
Calvarium lesions were more common in children, 
and mostly involved the occipital and parietal regions. 
The skull base involvements mostly involved the clivus, 
sphenoid bone and inner ear and were more common 
in adults. The chest wall, particularly the clavicle and 
sternum, was the second most common site involved 
after the skull. We could not find exact data on clav-
icular involvement, but some studies have reported its 
incidence in LCH disease [7, 9, 37–39]. Consistent with 
the findings of these studies, we only found five cases of 
clavicular involvement. The sternum was the other rare 
location; to the best of our knowledge, only 13 cases of 
sternum LCH have been reported in the literature, and 
seven of them (six unifocal and one multifocal) were 
included in this study [43–45]. Scapular and humeral 
involvements were rare in this study, and our results 
showed only two case reports of scapular involvement, 
and one case of humeral involvement. Khung et  al. [9] 
believed that “scapular lesions are not uncommon in 
children”, but Pandey et al. [47] reported the scapula as a 
rare location of LCH; based on our findings, the scapula 
seems to be a rare presentation of LCH. Kim et al. [69] 
reported the humerus as a frequent site in children, but 
our findings did not support their results; further studies 
are warranted in this area.
The forearms, metacarpals and metatarsals were the 
other rare sites found in our study, and they were previ-
ously reported to be rare or sporadic [2, 9, 14, 15].
As expected, localized pain and swelling or both were 
the most presenting signs in these patients; however, 
depending on the involved site and its severity, the symp-
toms were different. Our findings revealed the loss of 
consciousness with or without headache and vomiting 
due to extradural hematoma with LCH and myelopathy 
signs due to spinal cord compression, nerve palsy due to 
petrous apex involvement, and visual loss due to optic 
canal involvement, which are rare presentations of LCH 
[9, 12]. The presentation of LCH with extradural hema-
toma is an extremely rare presentation of the disease, and 
only ten cases have been reported in the literature [30]. 
We have identified nine of them in this review. Bleed-
ing can be spontaneous and nontraumatic or traumatic. 
In cases with spontaneous bleeding, the exact etiology is 
unknown [30]. Four of the cases that we reviewed had a 
history of mild trauma, but the remainder did not.
Cord compression and neurologic deficits due to spi-
nal involvement are extremely rare, and the threatening 
event of LCH usually present as localized or radiating 
pain, restricted mobility, numbness, weakness and par-
esthesia [31–35]. Khung et  al. [9] reported that isolated 
cervical spine involvement is very rare, but Shaker et al. 
[57] believed that, based on the literature review, the cer-
vical spine, compared with the thoracic or lumbar spine, 
has a higher prevalence. Therefore, for these conflict-
ing results, we only included the pathological fracture 
or cord compression with spinal involvements. Addi-
tionally, involvement of the atlantoaxial joint, maxillary 
sinus, bilateral jaw, acetabulum, sacral spine (in adults), 
the crest and posterior of the ilium, and two cases of the 
femur involvement were reported as rare presentations of 
LCH [9, 50, 54, 56, 57, 63, 65–67] and were included in 
our results.
Consistent with previous studies, our findings revealed 
that imaging analyses, including plain radiograph, CT 
and MRI play crucial roles in the diagnosis of bone 
involvements. Based on the available study findings [9, 
11, 13], most of the bone lesions were the osteolytic type. 
Additionally, intracranial hemorrhage, fluid–fluid levels, 
dura, intracranial extension, and pathological fractures 
were the rare radiologic features of LCH patients.
As mentioned previously, the treatment and outcome 
of bone lesions depend on their location, extent, and 
severity [6, 9]. Unifocal bone lesions have the best prog-
nosis and are usually managed by observation or locally 
by excision, curettage, steroid injection or radiation ther-
apy. Lesions that do not heal spontaneously or for which 
surgery is difficult require radiation or chemotherapy. 
By contrast, the multifocal and multisystem groups are 
usually treated using systemic chemotherapy [5, 11]. The 
current standard chemotherapy for the multifocal and 
low-risk multisystem groups is vinblastine and pred-
nisone and mercaptopurine plus vinblastine and pred-
nisone for the high-risk multisystem group. Clofarabine, 
cytarabine, etoposide and cladribine are salvage drugs [5, 
70]. The multisystem group with high risk organ involve-
ment has the worst prognosis [3].
Consistent with previous study findings [7, 49, 62], our 
findings revealed that local therapy and observation for 
the unifocal group, and systemic chemotherapy for the 
multifocal and multisystem groups were the most fre-
quent management approaches applied. As expected, the 
recovery rates of the unifocal and multifocal groups were 
higher than that of the multisystem group, and the rate of 
recurrence and mortality in the multisystem group was 
higher than that in the other groups. Unexpectedly, our 
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findings revealed that the recovery rate of the multifocal 
group (81.8) was higher than that of the unifocal group 
(77.3). The cause may be that, for the unifocal group, the 
follow-up data were not available for more patients com-
pared with those for the multifocal group.
Limitations
I. Given the incomplete data concerning patient follow-
up in this review and lack of long-term follow-up for 
cases, we cannot make judgments regarding the long-
term outcomes and reoccurrences of rare bone lesions of 
LCH in children or adults after treatment. Therefore, we 
suggest that future studies focus on exploring the long-
term outcomes of treating “unusual sites of bone involve-
ment in LCH patients”.
II. Additionally, our findings were derived from case 
reports, which rank at the bottom of the hierarchy of 
evidence. This inherent limitation in the study designs 
of the original articles covered in this systematic review 
restricts reaching a precise conclusion regarding the 
patient outcomes (i.e., rate of recovery, mortality rate, 
reoccurrence of symptoms, complications, and side 
effects).
Conclusion
LCH is a rare disease that can affect any organ in the 
human body. The bone is the most commonly involved 
organ, and rare bone involvements may be the first or 
only symptoms of the disease. Because of the rarity of 
these lesions, their unfamiliarity may lead to misdiag-
noses or delays in diagnosis. This review collected the 
clinical presentations, methods of diagnosis, radiologic 
features, management approaches, and outcomes of rare 
bone lesions of LCH in children and adults. Hopefully, 
our findings not only add to the body of literature con-
cerning LCH but also provide some clues or guidance for 
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Appendix
(“langerhans cell histiocytosis” OR “Hand-Schueller-
Christian Syndrome” OR “Hand Schueller Christian 
Syndrome” OR “Hand Schüller Christian Disease” OR 
“Hand-Schüller-Christian Syndrome” OR “Hand Schüller 
Christian Syndrome” OR “Histiocytosis X” OR “General-
ized Histiocytoses” OR “Generalized Histiocytosis” OR 
“Histiocytosis-X” OR “Langerhans Cell Histiocytoses” 
OR “Langerhans-Cell Granulomatosis” OR “Letterer-
Siwe Disease” OR “Letterer Siwe Disease” OR “Non-Lipid 
Reticuloendotheliosis” OR “Non Lipid Reticuloendotheli-
osis” OR “Non-Lipid Reticuloendothelioses” OR “Schuel-
ler-Christian Disease” OR “Schueller Christian Disease” 
OR “Systemic Aleukemic Reticuloendotheliosis” OR 
“Systemic Aleukemic Reticuloendothelioses” OR “Type 
2 Histiocytosis” OR “Type 2 Histiocytoses” OR “Langer-
hans Cell Granulomatosis” OR “Langerhans Cell Granu-
lomatoses” OR “Hand-Schueller-Christian Disease” OR 
“Pulmonary Histiocytosis X” OR “Pulmonary Langer-
hans Cell Granulomatosis” OR “Hashimoto-Pritzger 
Disease”) AND (Head OR neck OR otorhinolaryngology 
OR Otology OR Laryngology OR Lung OR Skin OR Skull 
OR Bone OR Condyle OR Skin OR Lung OR Liver OR 
“Hematopoietic System” OR “Lymph Node” OR “Endo-
crine System” OR “Gastrointestinal System” OR “Central 
Nervous System” OR “Cerebrospinal Axis” OR “Cere-
brospinal Axi”) AND (Pediatric OR Adult) AND (“Case 
report”)
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